The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Galantamine-induced Amyloid-β Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors
Open accessAbstract
Reduction of brain amyloid-β (Aβ) has been proposed as a therapeutic target for Alzheimer disease (AD), and microglial Aβ phagocytosis is noted as an Aβ clearance system in brains. Galantamine is an acetylcholinesterase inhibitor approved for symptomatic treatment of AD. Galantamine also acts as an allosterically potentiating ligand (APL) for nicotinic acetylcholine receptors (nAChRs). APL-binding site is located close to but distinct from that for acetylcholine on nAChRs, and FK1 antibody specifically binds to the APL-binding site without interfering with the acetylcholine-binding site. We found that in human AD brain, microglia accumulated on Aβ deposits and expressed α7 nAChRs including the APL-binding site recognized with FK1 antibody. Treatment of rat microglia with galantamine significantly enhanced microglial Aβ phagocytosis, and acetylcholine competitive antagonists as well as FK1 antibody inhibited the enhancement. Thus, the galantamine-enhanced microglial Aβ phagocytosis required the combined actions of an acetylcholine competitive agonist and the APL for nAChRs. Indeed, depletion of choline, an acetylcholine-competitive α7 nAChR agonist, from the culture medium impeded the enhancement. Similarly, Ca(2+) depletion or inhibition of the calmodulin-dependent pathways for the actin reorganization abolished the enhancement. These results suggest that galantamine sensitizes microglial α7 nAChRs to choline and induces Ca(2+) influx into microglia. The Ca(2+)-induced intracellular signaling cascades may then stimulate Aβ phagocytosis through the actin reorganization. We further demonstrated that galantamine treatment facilitated Aβ clearance in brains of rodent AD models. In conclusion, we propose a further advantage of galantamine in clinical AD treatment and microglial nAChRs as a new therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Galantamine activates microglia resulting in enhanced Aβ clearance [16].”
From Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease (2014) · cites this paper as [16]
In the citing paper
“galantamine has been shown to enhance microglial Aβ clearance [16].”
From Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease (2014) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Massagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,571
Rho GTPases and the Actin Cytoskeleton
Hall, A. (1998) · Science · doi:10.1126/science.279.5350.509 · Cited by 6,138
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation
Coyle, J. T., Price, D. L., & DeLong, M. R. (1983) · Science · doi:10.1126/science.6338589 · Cited by 3,052
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
Flagged first, then by citations
1 of the 60 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
Kwon, H. S., & Koh, S.-H. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00221-2 · Cited by 2,595
Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases
Tang, Y., & Le, W. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9070-5 · Cited by 2,190
Innate immunity in Alzheimer's disease
Heneka, M. T., Golenbock, D. T., & Latz, E. (2015) · Nature Immunology · doi:10.1038/ni.3102 · Cited by 902
The Gut Microbiota and Alzheimer’s Disease
Jiang, C., Li, G., Huang, P., Liu, Z., & Zhao, B. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161141 · Cited by 852
Bioinorganic Chemistry of Alzheimer’s Disease
Kepp, K. P. (2012) · Chemical Reviews · doi:10.1021/cr300009x · Cited by 683
Stansley, B., Post, J., & Hensley, K. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-115 · Cited by 419
Parsons, C. G., Danysz, W., Dekundy, A., & Pulte, I. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9398-z · Cited by 346
Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection.
Egea, J., Buendía, I., Parada, E., Navarro, E., León, R., & López, M. G. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.032 · Cited by 292
The biological pathways of Alzheimer disease: a review
Calabrò, M., Rinaldi, C., Santoro, G., & Crisafulli, C. (2020) · AIMS neuroscience · doi:10.3934/neuroscience.2021005 · Cited by 287
Inhibitors of Acetylcholinesterase and Butyrylcholinesterase Meet Immunity
Pohanka, M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15069809 · Cited by 252
Alzheimer’s disease as an inflammatory disease
Bolós, M., Perea, J. R., & Avila, J. (2017) · BioMolecular Concepts · doi:10.1515/bmc-2016-0029 · Cited by 216
Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease
Parri, H. R., Hernandez, C. M., & Dineley, K. T. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.039 · Cited by 187
Ahmad, M. H., Fatima, M., & Mondal, A. C. (2018) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.10.034 · Cited by 201
Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity
Halder, N., & Lal, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660342 · Cited by 190
Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders
Kalkman, H. O., & Feuerbach, D. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2175-4 · Cited by 191
Jiang, Y., Li, K., Li, X., Xu, L., & Yang, Z. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109452 · Cited by 154
Bhattacharya, S., Haertel, C., Maelicke, A., & Montag, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089454 · Cited by 142
Self-citationMisra, S., Chopra, K., Sinha, V. R., & Medhi, B. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1089956 · Cited by 136
β-Amyloid and the Pathomechanisms of Alzheimer’s Disease: A Comprehensive View
Penke, B., Bogár, F., & Fülöp, L. (2017) · Molecules · doi:10.3390/molecules22101692 · Cited by 150
Cholinergic Modulation of Glial Function During Aging and Chronic Neuroinflammation
Gamage, R. V., Wagnon, I. M., Rossetti, I., Childs, R., Niedermayer, G., Chesworth, R., & Gyengési, E. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.577912 · Cited by 134
Moreira, N. C. D. S., Lima, J. E. B. D. F., Marchiori, M. F., Carvalho, I., & Sakamoto‐Hojo, E. T. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210061 · Cited by 137
Kawamata, J., & Shimohama, S. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110173 · Cited by 111
Self-citationBenfante, R., Lascio, S. D., Cardani, S., & Fornasari, D. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01359-4 · Cited by 102
Microglial Function in the Effects of Early-Life Stress on Brain and Behavioral Development
Catale, C., Gironda, S. C., Iacono, L. L., & Carola, V. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020468 · Cited by 108
A novel cell line from spontaneously immortalized murine microglia
Nagamoto‐Combs, K., Kulas, J. A., & Combs, C. K. (2014) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2014.05.021 · Cited by 95
Atanasova, M., Stavrakov, G., Philipova, I., Zheleva, D., Yordanov, N., & Doytchinova, I. A. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.07.058 · Cited by 95
Han, B., Li, X., & Hao, J. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.002 · Cited by 97
Zueva, I. V., Dias, J., Lushchekina, S. V., Semenov, V. E., Mukhamedyarov, M. A., Pashirova, T. N., Babaev, V. M., Nachon, F., Petrova, N. V., Faritovich, N. L., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.025 · Cited by 91
Echeverría, V., Iarkov, A., & Aliev, G. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.002 · Cited by 95
Multitarget drugs of plants origin acting on Alzheimer’s disease
Russo, P., Frustaci, A., Del Bufalo, A., Fini, M., & Cesario, A. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130008 · Cited by 88
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease
Fontana, I. C., Kumar, A., & Nordberg, A. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00792-4 · Cited by 86
Wazea, S. A., Wadie, W., Bahgat, A. K., & El-Abhar, H. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-23359-6 · Cited by 79
Anwar, S., & Rivest, S. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1738391 · Cited by 78
Toward a Rational Design to Regulate β-Amyloid Fibrillation for Alzheimer’s Disease Treatment
Han, X., & He, G. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00477 · Cited by 77
Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond
Koola, M. M. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113409 · Cited by 77
Nanotechnology to improve the Alzheimer’s disease therapy with natural compounds
Ramalho, M. J., Andrade, S., Loureiro, J. A., & do Carmo Pereira, M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00694-3 · Cited by 75
Microglia as Dynamic and Essential Components of the Amyloid Hypothesis
Gandy, S., & Heppner, F. L. (2013) · Neuron · doi:10.1016/j.neuron.2013.05.007 · Cited by 74
An update on drug treatment options of Alzheimer's disease
Allgaier, M. (2014) · Frontiers in bioscience · doi:10.2741/4285 · Cited by 69
Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease
Baseman, A. S., Häger, K., Nye, J. S., Brashear, R. H., Han, J., Sano, M., Davis, B. M., & Richards, H. M. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s57909 · Cited by 69
Takata, K., Amamiya, T., Mizoguchi, H., Kawanishi, S., Kuroda, E., Kitamura, R., Ito, A., Saito, Y., Tawa, M., Nagasawa, T., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.10.021 · Cited by 68
Self-citationAntioxidant Activity of Galantamine and Some of its Derivatives
Tsvetkova, D. D., Obreshkova, D. P., Zheleva‐Dimitrova, D., & Saso, L. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990148 · Cited by 65
Shang, J., Yamashita, T., Zhai, Y., Nakano, Y., Morihara, R., Fukui, Y., Hishikawa, N., Ohta, Y., & Abe, K. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151126 · Cited by 64
Xu, Y., Au, N. P. B., & Ma, C. H. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.896852 · Cited by 68
Neurotoxicity evoked by organophosphates and available countermeasures
Pulkrabkova, L., Svobodová, B., Konecny, J., Kobrlová, T., Múčková, Ľ., Janousek, J., Pejchal, J., Korábečný, J., & Soukup, O. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03397-w · Cited by 63
Nicotinic Acetylcholine Receptor Signaling in Neuroprotection
Akaike, A., Shimohama, S., & Misu, Y. (2018) · Springer eBooks · doi:10.1007/978-981-10-8488-1 · Cited by 61
Self-citationTakata, K., Takada, T., Ito, A., Asai, M., Tawa, M., Saito, Y., Ashihara, E., Tomimoto, H., Kitamura, Y., & Shimohama, S. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/685739 · Cited by 60
Self-citationMohamed, L. A., Qosa, H., & Kaddoumi, A. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00040 · Cited by 58
Antidiabetic Effect of Galantamine: Novel Effect for a Known Centrally Acting Drug
Ali, M. A., El-Abhar, H. S., Kamel, M. A. E.-N., & Attia, A. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134648 · Cited by 56
Sadigh‐Eteghad, S., Majdi, A., Mahmoudi, J., Golzari, S. E., & Talebi, M. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1580-z · Cited by 53
Importance of GPCR-Mediated Microglial Activation in Alzheimer’s Disease
Haque, M. E., Kim, I., Jakaria, M., Akther, M., & Choi, D. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00258 · Cited by 55
Gao, J., Inagaki, Y., Li, X., Kokudo, N., & Tang, W. (2013) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2013.v7.2.46 · Cited by 52
Formulation and Evaluation of Galantamine Gel as Drug Reservoir in Transdermal Patch Delivery System
Woo, F.-Y., Basri, M., Ahmad, M. B., & Ismail, M. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/495271 · Cited by 51
Yokokawa, K., Iwahara, N., Hisahara, S., Emoto, M. C., Saito, T., Suzuki, H., Manabe, T., Matsumura, A., Matsushita, T., Suzuki, S., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190817 · Cited by 48
Self-citationKawanishi, S., Takata, K., Itezono, S., Nagayama, H., Konoya, S., Chisaki, Y., Toda, Y., Nakata, S., Yano, Y., Kitamura, Y., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170994 · Cited by 47
Self-citationNeuroinflammation Modulation via α7 Nicotinic Acetylcholine Receptor and Its Chaperone, RIC-3
Mizrachi, T., Vaknin‐Dembinsky, A., Brenner, T., & Treinin, M. (2021) · Molecules · doi:10.3390/molecules26206139 · Cited by 46
Galantamine-Curcumin Hybrids as Dual-Site Binding Acetylcholinesterase Inhibitors
Stavrakov, G., Philipova, I., Lukarski, A., Atanasova, M., Zheleva‐Dimitrova, D., Zhivkova, Z. D., Ivanov, S. M., Atanasova, T., Konstantinov, S., & Doytchinova, I. A. (2020) · Molecules · doi:10.3390/molecules25153341 · Cited by 44
Saito, T., Hisahara, S., Iwahara, N., Emoto, M. C., Yokokawa, K., Suzuki, H., Manabe, T., Matsumura, A., Suzuki, S., Matsushita, T., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.09.014 · Cited by 42
Self-citationMicroglial Phagocytosis—Rational but Challenging Therapeutic Target in Multiple Sclerosis
Pinto, M. V., & Fernandes, A. M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175960 · Cited by 42
Shen, Y., Zhao, M., Zhao, P., Meng, L., Zhang, Y., Zhang, G., Taishi, Y., & Sun, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1408462 · Cited by 45
Takata, K., Ginhoux, F., & Shimohama, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114754 · Cited by 40
Self-citationMorioka, N., Tokuhara, M., Nakamura, Y., Idenoshita, Y., Harano, S., Zhang, F. F., Hisaoka‐Nakashima, K., & Nakata, Y. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.11.044 · Cited by 39
Bhattacharya, S., Maelicke, A., & Montag, D. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142421 · Cited by 39
Self-citationURMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer’s disease
Kiyota, T., Machhi, J., Lu, Y., Dyavarshetty, B., Nemati, M., Zhang, G., Mosley, R. L., Gelbard, H. A., & Gendelman, H. E. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1172-y · Cited by 39
Dey, A., & Mukherjee, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809593-5.00006-9 · Cited by 40
Signaling of nicotinic acetylcholine receptors in mononuclear phagocytes
Richter, K., & Grau, V. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106727 · Cited by 39
The dialog between neurons and microglia in Alzheimer's disease: The neurotransmitters view
Stolero, N., & Frenkel, D. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15262 · Cited by 37
Calcium ion influx in microglial cells: Physiological and therapeutic significance
Sharma, P., & Ping, L. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23344 · Cited by 39
Molecular Docking Study on Galantamine Derivatives as Cholinesterase Inhibitors
Atanasova, M., Yordanov, N., Dimitrov, I., Berkov, S. H., & Doytchinova, I. A. (2015) · Molecular Informatics · doi:10.1002/minf.201400145 · Cited by 36
Galantamine attenuates amyloid-β deposition and astrocyte activation in APP/PS1 transgenic mice
Wu, Z., Zhao, L., Chen, X., Cheng, X., & Zhang, Y. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.10.015 · Cited by 36
Autism - A Neurodevelopmental Journey from Genes to Behaviour
Eapen, V. (2011) · InTech eBooks · doi:10.5772/974 · Cited by 36
Fujikura, M., Iwahara, N., Hisahara, S., Kawamata, J., Matsumura, A., Yokokawa, K., Saito, T., Manabe, T., Matsushita, T., Suzuki, S., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180904 · Cited by 36
Self-citationRegulation of microglia by neuromodulators: Modulations in major and minor modes
Albertini, G., Etienne, F., & Roumier, A. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135000 · Cited by 35
Nicotinic acetylcholine receptors mediate donepezil‐induced oligodendrocyte differentiation
Imamura, O., Arai, M., Dateki, M., Ogata, T., Uchida, R., Tomoda, H., & Takishima, K. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13294 · Cited by 35
Takata, K., & Kitamura, Y. (2012) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11r10fm · Cited by 35
Self-citationIwahara, N., Hisahara, S., Kawamata, J., Matsumura, A., Yokokawa, K., Saito, T., Fujikura, M., Manabe, T., Suzuki, H., Matsushita, T., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160887 · Cited by 34
Self-citationShang, J., Yamashita, T., Zhai, Y., Nakano, Y., Morihara, R., Li, X., Tian, F., Liu, X., Huang, Y. C., Shi, X., et al. (2018) · Neuroscience Research · doi:10.1016/j.neures.2018.06.002 · Cited by 33
Stavrakov, G., Philipova, I., Zheleva‐Dimitrova, D., Valkova, I., Salamanova, E., Konstantinov, S., & Doytchinova, I. A. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12991 · Cited by 33
Li, L., Li, L., Zhang, J., Huang, S., Liu, W., Wang, Z., Liang, S., Tao, J., & Chen, L. (2020) · Neural Plasticity · doi:10.1155/2020/8836173 · Cited by 33
Simeonova, R., Zheleva‐Dimitrova, D., Valkova, I., Stavrakov, G., Philipova, I., Atanasova, M., & Doytchinova, I. A. (2021) · Molecules · doi:10.3390/molecules26071865 · Cited by 32
Decourt, B., Noorda, K., Noorda, K. J., Shi, J., & Sabbagh, M. N. (2022) · Journal of Experimental Pharmacology · doi:10.2147/jep.s265626 · Cited by 33
Easton, A. E., Sankaranarayanan, S., Tanghe, A., Terwel, D., Lin, A., Hoque, N., Bourin, C., Gu, H., Ahlijanian, M. K., & Bristow, L. J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3152-3 · Cited by 33
Lane, R. M., & Darreh‐Shori, T. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142268 · Cited by 30
Rajkumar, M., Sakthivel, M., Senthilkumar, K., Thangaraj, R., & Kannan, S. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100100 · Cited by 29
Atta, A. A., Ibrahim, W. W., Mohamed, A. F., & Abdelkader, N. F. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175810 · Cited by 29
El-Ganainy, S. O., Gowayed, M. A., Agami, M. A., Mohamed, P., Belal, M., Farid, R. M., & Hanafy, A. S. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0051 · Cited by 28
Chrysanthou, M., Estruch, I. M., Rietjens, I. M. C. M., Wichers, H. J., & Hoppenbrouwers, T. (2022) · Nutrients · doi:10.3390/nu14020363 · Cited by 31
Takata, K., Kimura, H., Yanagisawa, D., Harada, K., Nishimura, K., Kitamura, Y., Shimohama, S., & Tooyama, I. (2022) · Molecules · doi:10.3390/molecules27092780 · Cited by 29
Self-citationThe mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation
Dong, W., Embury, C. M., Lu, Y., Whitmire, S. M., Dyavarshetty, B., Gelbard, H. A., Gendelman, H. E., & Kiyota, T. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0646-z · Cited by 28
Shimohama, S., & Kawamata, J. (2018) · Springer eBooks · doi:10.1007/978-981-10-8488-1_8 · Cited by 33
Self-citationSteiner, L., Gold, M., Mengel, D., Dodel, R. C., & Bach, J. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.06.032 · Cited by 27
Docking-based Design of Galantamine Derivatives with Dual-site Binding to Acetylcholinesterase
Stavrakov, G., Philipova, I., Zheleva‐Dimitrova, D., Atanasova, M., Konstantinov, S., & Doytchinova, I. A. (2016) · Molecular Informatics · doi:10.1002/minf.201600041 · Cited by 28
Diagnoses of Pathological States Based on Acetylcholinesterase and Butyrylcholinesterase
Pohanka, M. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190130161202 · Cited by 27
Targeted drug delivery systems to control neuroinflammation in central nervous system disorders
Mozafari, N., Ashrafi, H., & Azadi, A. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102802 · Cited by 25
Complexity of Sex Differences and Their Impact on Alzheimer’s Disease
Kadlecová, M., Freude, K., & Haukedal, H. (2023) · Biomedicines · doi:10.3390/biomedicines11051261 · Cited by 27
Kuroda, E., Nishimura, K., Kawanishi, S., Sueyoshi, M., Ueno, F., Toji, Y., Abo, N., Konishi, T., Harada, K., Satake, S., et al. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.05.004 · Cited by 24
Self-citationMorioka, N., Harano, S., Tokuhara, M., Idenoshita, Y., Zhang, F. F., Hisaoka‐Nakashima, K., & Nakata, Y. (2015) · Brain Research · doi:10.1016/j.brainres.2015.08.029 · Cited by 24
Liu, S.-Z., Cheng, W., Shao, J.-W., Gu, Y.-F., Zhu, Y., Dong, Q.-J., Bai, S., Wang, P., & Li, L. (2019) · Current Medical Science · doi:10.1007/s11596-019-2019-1 · Cited by 23
Nakamura, Y., Kimura, S., Takada, N., Takemura, M., Iwamoto, M., Hisaoka-Nakashima, K., Nakata, Y., & Morioka, N. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104751 · Cited by 18
Liu, N., Haziyihan, A., Zhao, W. G., Chen, Y., & Chao, H. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00434-9 · Cited by 21
Donepezil suppresses intracellular Ca2+ mobilization through the PI3K pathway in rodent microglia
Haraguchi, Y., Mizoguchi, Y., Ohgidani, M., Imamura, Y., Murakawa‐Hirachi, T., Nabeta, H., Tateishi, H., Kato, T. A., & Monji, A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1033-0 · Cited by 22
Metadata
- Authors
- Takata, K., Kitamura, Y., Saeki, M., Terada, M., Kagitani, S., Kitamura, R., Fujikawa, Y., Maelicke, A., Tomimoto, H., Taniguchi, T., & Shimohama, S.
- Affiliations
- Kyoto Pharmaceutical University (JP)
- Mie University (JP)
- Sapporo Medical University (JP)
- Corresponding author
- Kitamura, Yoshihisa
- Shimohama, Shun
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 285
- Issue
- 51
- Pages
- 40180-40191
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC3001000
- OpenAlex
- W2022036412
- Cited by
- 176
- References
- 60
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 7 · 2023: 11 · 2022: 10 · 2021: 12 · 2020: 16 · 2019: 13 · 2018: 11 · 2017: 13 · 2016: 16 · 2015: 16 · 2014: 8 · 2013: 12 · 2012: 6
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Keywords
- galantamine, amyloid-beta clearance, microglia, alpha7 nicotinic acetylcholine receptor, choline, calcium influx, actin reorganization, calmodulin signaling, Alzheimer's disease, microglial phagocytosis
- MeSH terms
- Aged, Alzheimer Disease, Animals, Antibodies, Monoclonal, Binding Sites, Calmodulin, Cells, Cultured, Choline, Cholinesterase Inhibitors, Disease Models, Animal, Female, Galantamine, Hippocampus, Humans, Male, Phagocytosis, Receptors, Nicotinic, Amyloid beta-Peptides, Rats, Wistar, Microglia, Nootropic Agents, Calcium Signaling, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
